XXX - Sitagliptin vs Bifidobacterium breve + Bifidobacterium longum + Fructooligosaccharides (FOS) + Lacticaseibacillus casei + Lacticaseibacillus rhamnosus + Lactobacillus acidophilus + Lactobacillus delbrueckii bulgaricus + Sitagliptin + Streptococcus thermophilus & Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD)

Background

Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver diseases in recent years (1)

Study overview

It is a randomized, clinical trial studying Sitagliptin (50 mg/daily) vs Bifidobacterium breve + Bifidobacterium longum + Fructooligosaccharides (FOS) + Lacticaseibacillus casei + Lacticaseibacillus rhamnosus + Lactobacillus acidophilus + Lactobacillus delbrueckii bulgaricus + Sitagliptin (50 mg/daily) + Streptococcus thermophilus (10^7 CFU/strain; 500 mg/daily/synbiotic capsule) in 138 enrolled patients with [Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD)](brain://0_T4lKylP0CsXkdsY4SiLw/NonAlcoholicFattyL…